Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

46P - Plasma soluble CD36 of breast cancer based on pathological and clinical characteristics


23 Nov 2019


Poster display session


Tumour Site

Breast Cancer


Aditia Romadhoni


Annals of Oncology (2019) 30 (suppl_9): ix13-ix19. 10.1093/annonc/mdz418


A.R. Romadhoni1, A. Rachman2, C. Irawan2, S. Koesnoe2

Author affiliations

  • 1 Internal Medicine, RSUPN (Rumah Sakit Cipto Mangunkusumo), 10430 - Jakarta/ID
  • 2 Internal Medicine, Cipto Mangunkusumo General Hospital (RSCM) University of Indonesia, 10430 - Jakarta/ID


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 46P


Breast cancer is one of the malignant diseases with the highest prevalence around the world, including Indonesia. Data from Global Cancer Statistics 2018 (GLOBOCAN) predicted that up to 2.1 billion women were diagnosed with breast cancer; therefore, it became one of the top four cancerous diseases in women. Several studies have revealed the role of CD36 molecule in breast cancer and there are several gaps in CD36 expression knowledge. In tumor adhesion, CD36 is involved in cellular interaction with collagen in the extracellular matrix. Some measurement methods of CD36 expression molecules include gene expression measurement through micro-assay, total RNA analysis, and plasma examination through ELISA techniques already done in subjects with non alcoholic fatty liver disease, diabetes mellitus, insulin resistance, coronary arterial disease, carotid atherosclerosis, chronic kidney disease, and ischaemic stroke. However, concentration measurement of CD36 plasma molecule in breast cancer using ELISA technique has not yet been done in previous studies.


This is a cross-sectional study, was held during June 2018 up to February 2019. Sampling methods were taken consecutively in 118 subjects, consisted of 76 BC subjects, 42 normal subjects. Inclusion criteria included women aged 18 to 70 years old, having pathological invasive breast cancers, and subjects were willing to sign the informed consent sheets. Exclusion criteria included subjects with disease progressivity during therapy, diabetes mellitus, stroke, liver, coronary arterial disease, chronic kidney disease. Subjects were then drawn 2 cc of the peripheral blood,and then was centrifuged in 3000 RPM for 15 minutes. After that, the plasma was analyzed with ELISA technique with reagent (Bioassay Technology Laboratory). Data was analyzed using SPSS for windows version 20.


Table: 46P

Profile of plasma CD36 concentration

CharacteristicMedian concentration CD36 (ng/mL)p
BC Healthy0.21 (-0.05 up to 0.70) 0.57 (0.13 up to 1.05)0.00
Metastatic BC Non metastatic BC0.21 (-0.05 up to 0.70) 0.21 (-0.05 up to 0.70)> 0.05
BC with LN metastatic BC without LN metastatic0.20 (-0.05 up to 0.70) 0.23 (-0.05 up to 0.70)> 0.05
Luminal tumor HER2 tumor Triple negative tumor0.21 (-0.05 up to 0.67) 0.21 (-0.02 up to 0.70) 0.22 (-0.02 up to 0.36)> 0.05
G1 G2 G3 Unknown grade0.23 (0.16 up to 0.70) 0.21 (-0.05 up to 0.70) 0,20 (-0,02 up to 0,67) 0.22 (0.10 up to 0.53)> 0.05
Tumor size > 2 cm Tumor size ≤ 2 cm0.21 (-0.05 up to 0.70) 0.26 (0.13 up to 0.70)> 0.05
BC with BMI≥ 23 BC with BMI < 230.20 (-0.05 up to 0.70) 0.23 (-0.05 up to 0.70)> 0.05


Plasma CD36 concentration of breast cancer is lower than the healthy. There are insignificant differences of plasma CD36 concentration profile breast cancer patients based on metastatic status, lymph node metastatic, molecular subtype, invasive cancer histologic grade, and body mass index.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The Ethics Committee of The Faculty of Medicine, University of Indonesia.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.